BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?